UBS Group AG - AXOVANT GENE THERAPIES LTD ownership

AXOVANT GENE THERAPIES LTD's ticker is AXGT and the CUSIP is G0750W203. A total of 45 filers reported holding AXOVANT GENE THERAPIES LTD in Q1 2020. The put-call ratio across all filers is 1.22 and the average weighting 0.1%.

Quarter-by-quarter ownership
UBS Group AG ownership history of AXOVANT GENE THERAPIES LTD
ValueSharesWeighting
Q3 2020$19,000
+375.0%
4,156
+211.5%
0.00%
Q2 2020$4,000
-82.6%
1,334
-70.1%
0.00%
Q4 2019$23,000
-90.3%
4,469
-87.8%
0.00%
Q3 2019$236,000
+29.7%
36,517
+25.3%
0.00%
Q2 2019$182,00029,1440.00%
Other shareholders
AXOVANT GENE THERAPIES LTD shareholders Q1 2020
NameSharesValueWeighting ↓
DAFNA Capital Management LLC 1,021,566$2,493,0001.04%
SPHERA FUNDS MANAGEMENT LTD. 2,931,018$7,152,0000.90%
Consonance Capital Management LP 3,653,303$8,914,0000.66%
Rubric Capital Management LP 460,200$1,123,0000.18%
Hudson Bay Capital Management LP 1,350,000$3,294,0000.08%
Ikarian Capital, LLC 188,884$461,0000.04%
GSA CAPITAL PARTNERS LLP 41,037$100,0000.02%
Spark Investment Management LLC 18,072$44,0000.02%
Cable Hill Partners, LLC 15,000$37,0000.01%
BOOTHBAY FUND MANAGEMENT, LLC 38,800$95,0000.01%
View complete list of AXOVANT GENE THERAPIES LTD shareholders